Brief: Spago Nanomedicals Expands Study With Spagopix Into New Indications Based On Results

Spago Nanomedical AB (publ)

13/01/2022 09:03

Jan 13 (Reuters) - Spago Nanomedical AB (publ)  SPAGO.ST 
    * SPAGO NANOMEDICALS PHASE 1 STUDY WITH SPAGOPIX SHOWS CLEAR
CONTRAST ENHANCEMENT AND IS EXPANDED INTO NEW INDICATIONS
    * SHOW THAT SPAGOPIX (SN132D) IS WELL TOLERATED AND PROVIDES
CLEAR
CONTRAST ENHANCEMENT IN MRI IMAGES OF SOLID TUMORS IN BREAST, AS
WELL AS IN PANCREAS AND LIVER.
    * BASED ON RESULTS, COMPANY HAS DECIDED TO CONTINUE STUDY IN
BREAST CANCER AND IN ADDITION, TO EXPAND TO ALSO INCLUDE
PATIENTS WITH PANCREATIC AND LIVER CANCER

Source text for Eikon:  ID:nMFNbyMct7 
Further company coverage:  SPAGO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))